Zai Lab Ltd. (ZLAB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of Zai Lab (ZLAB)

Zai Lab Limited (ZLAB) licenses global developments for China, minimizing risks and creating stable FCF. This EV/EBITDA ratio chart on GURU.Markets clearly displays historical data, where 0.00 determines the current status of the parameter. Cash flows are based on Asian sales despite pricing controls, while the strategy relies on the adaptation of foreign oncology drugs.

ZLAB Zai Lab Ltd: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization in the range 11/23/2025 - 11/10/2026

Analytical breakdowns for Zai Lab Limited

- current price and projected stock value:
Stock Price Zai Lab Ltd.|ZLAB - Fair Value Consensus
- market capitalization indicators:
Market Value Zai Lab Corp|ZLAB - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Zai Lab|ZLAB - Company Book Value|Market Capitalization to Book Value Ratio zailaboratory.com|ZLAB - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Zai Lab Limited|ZLAB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Zai Lab|ZLAB - Company Aggregate Debt|Debts to Book Capitalization Zai Lab Corp|ZLAB - Long-Term Indebtedness|Company Current Liabilities Zai Lab|Quick Ratio zailaboratory.com
- business earnings and investment ratios data:
ZLAB - Net Profit|Projected Future Earnings Zai Lab Limited|ZLAB - Business Payback Period|Projected Price to Earnings Zai Lab Limited|ZLAB - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zai Lab Corp|ZLAB - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Zai Lab|ZLAB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth zailaboratory.com|ZLAB - Earnings per share growth in current year|Expected earnings per share growth for next year Zai Lab Limited
Fundamental company valuation:Zai Lab Ltd. ZLAB
Product sample of Zai Lab

For a comparative asset analysis, the investor utilizes this multiple, comparing the total enterprise value including debt to operating profit before taxes. This model assesses cash flow generation efficiency, which is critical for Zai Lab Limited (ZLAB) when commercializing high-cost licensed drugs in China, reflecting the real business value within the company's historical EV/EBITDA trend.

Main competitors

EV/EBITDA Multiple LLY (Eli Lilly & Co.)|Business Value to Operating Income Before Depreciation ABBV|AZN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA novartis.com|Merck (MRK) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NVO (Novo Nordisk AS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AMGN (Amgen Corporation) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation PFE (Pfizer Corp)|EV/EBITDA Multiple SNY|Total Company Value to Operating Income Before Depreciation Ratio bms.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GlaxoSmithKline GSK|TAK: Enterprise Value to Operating Income Before Depreciation|Teva Pharmaceutical Industries Ltd. - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Dr. Reddy's Labs (RDY)|VTRS (Viatris Inc.) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio ROIV (roivant.com)|BHC (Bausch Health) - EV/EBITDA Multiple|EV/EBITDA Multiple Cosmos Health, Inc.